Pre-Clinical Evaluation of the PI3K-p110ß/δ Inhibitor KA2237 in Mantle Cell Lymphoma

Pre-Clinical Evaluation of the PI3K-p110ß/δ Inhibitor KA2237 in Mantle Cell Lymphoma. Huang S., Nastoupil L.J., Guo H., Bell T., Ahmed M., Li C.J., Wang J., Liu Y.,  Zhang V., Kim C.R., Boyle J.N., Lorence E.A., Lam L.T., Chen Z., Zhang H., Shuttleworth S.J., Nomie K., Wang M., Zhang L. Abstract 1837. 58th ASH Annual Meeting and […]

Karus Therapeutics features in BioCentury Innovations

Oxford, UK, 4 November 2016 – Karus Therapeutics, a leader in the design and development of innovative cancer therapeutics, was featured in BioCentury Innovations, ‘One Plus One Equals Four’. Chief Scientific Officer Stephen Shuttleworth details how lead program KA2237 can suppress tumor growth and metastasis directly, while dialing down PD-L1 and Tregs via different mechanisms […]

Karus Therapeutics presenting at BIO-Europe

Oxford, UK, 21 October 2016 – Karus Therapeutics Ltd, a leader in the development of innovative medicines for the treatment of cancer, has announced its CEO will be delivering a presentation at the 22nd BIO-Europe, Cologne, Germany, 7-9 November 2016. Dr Simon Kerry, Karus’s CEO, will be presenting on the Oncology track, taking place in the […]

Karus Therapeutics Announces First Lymphoma Patients Dosed with KA2237 in Clinical Study at the MD Anderson Cancer Center

First cohort of cancer patients has been dosed with Karus’s lead candidate, KA2237 Potential first-in-class dual-PI3K-p110β/δ inhibitor with broad potential to treat hematological and solid tumors KA2237 combines an immunotherapeutic response and a direct effect on tumor growth Oxford, UK, 5 October 2016 – Karus Therapeutics (‘Karus’), a leader in the development of innovative, orally-active […]

Karus Therapeutics giving lecture at BIO Investor

Oxford, UK, 3 October 2016 – Karus Therapeutics Ltd, a leader in the development of innovative medicines for the treatment of cancer, has announced its CEO will be delivering a lecture at the 15th Annual BIO Investor Forum, San Francisco, California, USA, 18-19 October 2016. Dr Simon Kerry, Karus’s CEO, will be lecturing on oncology as […]

Karus Therapeutics giving lecture at 10th Annual Symposium – Next Generation Histone Deacetylase Inhibitors

Oxford, UK, 7 September 2016 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer, has announced its CSO will be attending and delivering a lecture at the 9th Annual Kinase Inhibitor Discovery conference, Boston, USA, 19 September 2016. Stephen Shuttleworth, Karus’s CSO, will be lecturing in the session Role […]

Karus Therapeutics delivering lecture at 9th Annual Kinase Inhibitor Discovery conference

Oxford, UK, 1 September 2016 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer, has announced its CSO will be attending and giving a lecture at the 9th Annual Kinase Inhibitor Discovery conference, Boston, USA, 21-22 September 2016. Stephen Shuttleworth, Karus’s CSO, will be lecturing in the session Kinase […]

KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting PI3K-p110ß/p110δ and HDAC6 with single-agent and combination activity (Mainz)

KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting PI3K-p110ß/p110δ and HDAC6 with single-agent and combination activity. Alexander R., Bone E.A., Cecil A.R.L., Colman L., Dow J., Finnemore D., Gatland A., Haque K., Lensun L., Roitt S., Rogers H., Silva F.A., Ward P., Whale A., Shuttleworth S.J. Abstract 207. 14th CIMT Annual Meeting, Mainz, Germany, May 10-12, […]

Karus Therapeutics presenting at BioEquity 2016

Oxford, UK, 21 April 2016 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer has announced that it will be giving a company presentation at BioEquity 2016, Copenhagen, Denmark, 10-11 May 2016. Simon Kerry, Karus’s CEO, will be presenting on Wednesday, 11 May 2016 at 9:20am. For more […]

KA2237 and KA2507. Novel, oral cancer immunotherapeutics targeting PI3K-p110ß/p110δ and HDAC6 with single-agent and combination activity (New Orleans)

KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting PI3K-p110ß/p110δ and HDAC6 with single-agent and combination activity. Alexander R., Bone E.A., Cecil A.R.L., Colman L., Dow J., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Roitt S., Rogers H., Silva F.A., Ward P; Whale A., Shuttleworth S.J. In: Proceedings of the 107th Annual Meeting of […]